相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema
David Brown et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2022)
Brolucizumab - termination of 4 weekly trials - rebalancing the immunogenicity risk
Ashish Sharma et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
Louisa Maria Bulirsch et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2022)
Brolucizumab-early real-world experience: BREW study
Ashish Sharma et al.
EYE (2021)
Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration - Current Perspectives
Long T. Phan et al.
CLINICAL OPHTHALMOLOGY (2021)
Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration
Ramin Tadayoni et al.
OPHTHALMOLOGICA (2021)
RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Peter K. Kaiser et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2021)
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab Post Hoc Review of HAWK and HARRIER
Jordi Mones et al.
OPHTHALMOLOGY (2021)
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA
Adnan Tufail et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2020)
Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2020)
Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents
Rebecca N. Evans et al.
JAMA OPHTHALMOLOGY (2020)
Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
Frank G. Holz et al.
PLOS ONE (2020)
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen FLUID Study 24-Month Results
Robyn H. Guymer et al.
OPHTHALMOLOGY (2019)
OPTIMAL MANAGEMENT OF PIGMENT EPITHELIAL DETACHMENTS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Arshad M. Khanani et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Age-related macular degeneration
Paul Mitchell et al.
LANCET (2018)
Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
Kimberly Spooner et al.
CLINICAL OPHTHALMOLOGY (2017)
Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study)
Robert B. Bhisitkul et al.
OPHTHALMOLOGY (2016)
Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration Post Hoc Analysis of the HARBOR Study
David Sarraf et al.
OPHTHALMOLOGY (2016)
Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials
Sebastian M. Waldstein et al.
OPHTHALMOLOGY (2016)
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials
Sumit Sharma et al.
OPHTHALMOLOGY (2016)
Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD
Sebastian M. Waldstein et al.
OPHTHALMOLOGY (2016)
The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study
Jennifer J. Arnold et al.
BMC OPHTHALMOLOGY (2016)
Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)
Pigment Epithelial Detachment Followed by Retinal Cystoid Degeneration Leads to Vision Loss in Treatment of Neovascular Age-Related Macular Degeneration
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2015)
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
Ursula Schmidt-Erfurth et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Morphologic Parameters Relevant for Visual Outcome During Anti-Angiogenic Therapy of Neovascular Age-Related Macular Degeneration
Christian Simader et al.
OPHTHALMOLOGY (2014)
Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials
Gui-shuang Ying et al.
JAMA OPHTHALMOLOGY (2014)
Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
Brandon G. Busbee et al.
OPHTHALMOLOGY (2013)
Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
Gui-shuang Ying et al.
OPHTHALMOLOGY (2013)
Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
Glenn J. Jaffe et al.
OPHTHALMOLOGY (2013)
分享论文
